Journal article
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020.
Abstract
On December 18, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Moderna COVID-19 (mRNA-1273) vaccine (ModernaTX, Inc; Cambridge, Massachusetts), a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) (1). This vaccine is the second COVID-19 vaccine authorized …
Authors
Oliver SE; Gargano JW; Marin M; Wallace M; Curran KG; Chamberland M; McClung N; Campos-Outcalt D; Morgan RL; Mbaeyi S
Journal
MMWR Morbidity and Mortality Weekly Report, Vol. 69, No. 5152, pp. 1653–1656
Publisher
Centers for Disease Control MMWR Office
DOI
10.15585/mmwr.mm695152e1
ISSN
0149-2195
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AdolescentAdultAdverse Drug Reaction Reporting SystemsAdvisory CommitteesAgedAged, 80 and overCOVID-19COVID-19 VaccinesCenters for Disease Control and Prevention, U.S.Clinical Trials, Phase III as TopicDrug ApprovalEmergenciesHumansImmunizationMiddle AgedPractice Guidelines as TopicRandomized Controlled Trials as TopicUnited StatesUnited States Food and Drug AdministrationYoung Adult